Latest stock market news videos & Morning Bell
From the helm: Alterity Therapeutics (ASX:ATH), CEO, David Stamler.
In this episode of From the Helm, Grady chats with Alterity Therapeutics (ASX:ATH) CEO David Stamler, to discuss their neurodegenerative disorder treatment specifically targeting Multiple System Atrophy (MSA), a rare and aggressive disease affecting involuntary functions and motor control.
